8-K: MAIA Biotech Reports 30-Month NSCLC Survival in Phase 2 Trial

MAIA Biotechnology announced outstanding 30-month patient survival data from its ongoing Phase 2 clinical trial of ateganosine in non-small cell lung cancer.

Summary

• MAIA Biotechnology presented highlights from its Phase 2 (THIO-101) and Phase 3 (THIO-104) clinical trials of ateganosine for non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology (ESMO) Congress 2025.
• A patient in the THIO-101 Phase 2 trial, who began therapy in March 2023, has achieved 30 months (912 days) of survival as of September 17, 2025.
• This 30-month survival is considered an outstanding measure of efficacy for high-risk cancers with limited treatment options, particularly for third-line NSCLC patients resistant to prior immune checkpoint inhibitors (ICI) and chemotherapy.
• Ateganosine (THIO) is a first-in-class investigational telomere-targeting agent designed to induce telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death.
• The sequential treatment of ateganosine followed by PD-(L)1 inhibitors has shown profound and persistent tumor regression in advanced in vivo cancer models.
• The THIO-101 trial is evaluating ateganosine's anti-tumor activity when followed by PD-(L)1 inhibition (cemiplimab) in advanced NSCLC patients who previously did not respond or developed resistance to first-line treatment.
• The THIO-101 trial has shown an acceptable safety profile to date in a heavily pre-treated patient population.

Sentiment

Score: 9

Explanation: The filing reports highly positive clinical trial results, specifically 30-month patient survival in a challenging cancer indication (third-line NSCLC resistant to prior therapies). This 'outstanding measure of efficacy' suggests significant therapeutic potential and de-risks the asset considerably, leading to a very strong positive sentiment.

Positives

• Achieved 30-month (912 days) patient survival in the ongoing Phase 2 THIO-101 clinical trial for advanced Non-Small Cell Lung Cancer (NSCLC).
• The 30-month survival is an outstanding measure of efficacy for high-risk cancers with limited treatment options, especially for third-line NSCLC patients resistant to prior ICI and chemotherapy.
• Ateganosine demonstrates potential as an effective treatment for patients refractory or resistant to immune checkpoint inhibitors (ICI).
• The THIO-101 trial has shown an acceptable safety profile in a heavily pre-treated patient population.

Risks

• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from those anticipated.
• Risks include those related to the initiation, timing, cost, progress, and results of preclinical and clinical studies and research and development programs.
• Uncertainties exist regarding the ability to advance product candidates into, and successfully complete, clinical studies.
• Risks associated with the timing or likelihood of regulatory filings and approvals.
• Challenges in the ability to develop, manufacture, and commercialize product candidates and improve the manufacturing process.
• Uncertainties regarding the rate and degree of market acceptance of product candidates.
• Risks related to the size and growth potential of the markets for product candidates and the ability to serve those markets.
• Challenges in obtaining and maintaining intellectual property protection for product candidates.

Future Outlook

The company's future outlook includes the continued progression of its preclinical and clinical studies, particularly the ongoing Phase 2 and Phase 3 trials for ateganosine. Management anticipates advancing product candidates, seeking regulatory approvals, and eventually commercializing its therapies. The company also expects to obtain and maintain intellectual property protection for its product candidates and serve the target markets.

Management Comments

• "a patient that began therapy in March 2023 has shown survival of 30 months, or 912 days, an outstanding measure relative to many of the high-risk cancers."
• "Very few options exist for patients who are refractory or resistant to immune checkpoint inhibitors (ICI). We believe that a survival of over two years is a clear signal of ateganosines role in effectively targeting and eliminating NSCLC tumor cells."

Industry Context

This announcement positions MAIA Biotechnology as a significant player in the targeted immunotherapy and immuno-oncology space, particularly for Non-Small Cell Lung Cancer (NSCLC). The focus on patients resistant to standard immune checkpoint inhibitors addresses a critical unmet medical need in a large oncology market. The novel telomere-targeting mechanism of ateganosine differentiates it from existing therapies and aligns with the industry trend towards developing more precise and effective treatments for difficult-to-treat cancers.

Comparison to Industry Standards

• The 30-month survival in third-line NSCLC patients, who are resistant to prior ICI and chemotherapy, is an exceptional outcome given the typically poor prognosis and limited treatment options for this patient population.
• This survival data is considered an 'outstanding measure of efficacy' relative to many high-risk cancers, suggesting ateganosine could significantly outperform current standards of care for ICI-resistant advanced NSCLC.

Stakeholder Impact

• Shareholders: Likely positive impact due to promising clinical data, potentially increasing investor confidence and stock valuation.
• Patients: Offers hope for a new, effective treatment option for advanced NSCLC, especially those who have exhausted current standard-of-care therapies.
• Medical Community: Provides new data on a novel telomere-targeting agent, potentially influencing future treatment paradigms for NSCLC.
• Employees: Positive impact on morale and company outlook due to successful clinical progress.

Next Steps

• Continue ongoing Phase 2 (THIO-101) and Phase 3 (THIO-104) clinical trials for ateganosine in NSCLC.
• Assess overall response rates (ORR) in the expansion of the THIO-101 study.
• Further development and potential commercialization of ateganosine.

Key Dates

Recommendation

The reported 30-month patient survival in the Phase 2 THIO-101 trial for third-line NSCLC patients, who are resistant to prior immune checkpoint inhibitors and chemotherapy, represents a highly significant clinical achievement. This 'outstanding measure of efficacy' in a patient population with extremely limited treatment options and poor prognosis substantially de-risks ateganosine and indicates a strong potential for market penetration and future revenue. Given the unmet medical need and the compelling clinical data, a seasoned investor would view this as a strong buy opportunity, anticipating significant future value creation.

Keywords

MAIA Biotechnology, ateganosine, THIO, NSCLC, non-small cell lung cancer, immunotherapy, cancer, clinical trial, Phase 2, Phase 3, ESMO, oncology, telomere-targeting, immune checkpoint inhibitor, ICI, survival data